

Product/Dosing

Reference for Clinicians

Active Ingredients:

Formula C contains a complex blend of hemp derived terpenes specifically designed to attenuate the symptoms of Long Covid.

**Patients with employers that have prohibitions on and test for Phytocannabinoids should consult with their human resources department prior to use.*

FORMULA C™

Long COVID (PASC) Symptoms

Formulation

Modality

Initial Dose

Titration

(i) Ability to Participate in Social Roles, (ii) Cognitive Function, (iii) Satisfaction with Social Roles & Activities, (iv) Dyspnea Severity, (v) Emotional Distress Anxiety, (vi) Emotional Distress Depression, (vii) Fatigue, (viii) Pain, (ix) Sleep Disturbance

Formula C^{1,2}

Sublingual

¼ Dropper 2X Daily

Q 4 days PRN



Primary indications

Anxiety | Depression | Fatigue | Sleep Disturbance

Dosage instructions

Days 1 - 3 0.25mL (1/4 dropper) twice per day

If not tolerated decrease dose to 4 drops twice per day.
Can further reduce to 1-2 drops twice per day.

Day 4 If tolerated, increase dose by 0.25mL to 0.5mL twice per day

Day 11 If tolerated, increase dose by 0.25mL to 0.75mL twice per day

Day 18 If tolerated, increase dose by 0.25mL to 1 mL twice per day

Day 25 Adjust dose up or down as desired.

Q (“frequency”); PRN (“pro re nata” meaning “or as needed”) Patients who respond to a Targeted Formulation in the short term are encouraged to transition to Maintenance Dosing in the longer term by titrating down

For more information, clinicians can directly access Endourage support at clinicianconciierge@endourage.com or call 855-920-7546

¹ A Single-Blind, Randomized, Placebo Controlled Study to Evaluate the Benefits and Safety of Endourage Targeted Wellness Formula C Sublingual +Drops in People with Post-Acute Coronavirus Disease 2019 Syndrome Thomas P. Young, Joel S. Erickson, Shannon L. Hattan, Serge Guzy, Fabienne Hershkowitz, and Michael D. Steward Cannabis and Cannabinoid Research 0 0:0

² Steward M, Wisneski L*. Full-Spectrum Phytocannabinoids: A Whole-Plant Holistic Approach for Maintaining Optimal Endocannabinoid Tone and Potentially Attenuating the Effects of Acute and Post-Acute Coronavirus-Induced Disease. Adv Complement Alt Med. 7(4). ACAM. 000667. 2023. DOI: 10.31031/ACAM.2023.07.000667